Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13.
about
The role of NKT cells in tumor immunityBlockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.A comprehensive ex vivo functional analysis of human NKT cells reveals production of MIP1-α and MIP1-β, a lack of IL-17, and a Th1-bias in malesGlycolipid antigens for treating hepatic colorectal cancer metastases and their effect on the therapeutic efficacy of live attenuated Listeria monocytogenesStrategies to use immune modulators in therapeutic vaccines against cancerInduction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity.Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammationAccumulation of invariant NKT cells with increased IFN-γ production in persistent high-risk HPV-infected high-grade cervical intraepithelial neoplasia.A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses.NKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases.Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development.A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance.Delicate balance among three types of T cells in concurrent regulation of tumor immunity.IL-13 induces the expression of 11βHSD2 in IL-13Rα2 dependent manner and promotes the malignancy of colorectal cancer.Th2-mediated anti-tumour immunity: friend or foe?Gene Therapy against Murine Melanoma B16F10-Nex2 Using IL-13Ralpha2-Fc Chimera and Interleukin 12 in Association with a Cyclopalladated DrugMultiple roles for CD4+ T cells in anti-tumor immune responses.Type I natural killer T cells suppress tumors caused by p53 loss in mice.β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergyThe contrasting roles of NKT cells in tumor immunity.Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response.Type I natural killer T cells: naturally born for fighting.Unravelling the complexity of cancer-immune system interplay.Intestinal inflammation and colorectal cancer: a double-edged sword?The role of natural killer T cells in B cell malignancies.Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.Induction of thymic stromal lymphopoietin in mesenchymal stem cells by interaction with myeloma cells.Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer.The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach.
P2860
Q24648939-7F026AE4-C8A8-4EE3-852E-4B119B26972BQ33637647-1F67EE25-296F-4945-A4F7-D3042EBE4E7EQ33748552-A6FC73B8-A2E3-4EDA-B1E2-34E07C025035Q34089577-ECF32A26-040A-413F-92FA-050EFE94F24EQ34275601-560E72C7-2A1E-4132-A659-B4B021E9F903Q34312794-6307B8D2-F186-4C90-924B-C1F80BF8C8F8Q34519826-6D1F33E5-54EF-4DB5-B96F-B3C99BE49457Q34681491-8ECAC1C7-D0CB-423D-91C5-9AC52D69F1BCQ35559432-CCD61327-487F-4779-B6A8-76CDAA5DCFDAQ35871793-568BC069-1F60-428D-97B0-191CEF77B4A9Q35956535-B4AAECEA-8C96-4AD9-9E81-BAEABBC43B68Q36229313-0874861B-0708-48C8-975F-2FDFB0AF193CQ36403071-0CEBD4D8-039A-4A35-9121-5F9F50843400Q36755513-E748CE8C-098D-46D9-A76A-1D99C8575167Q36841327-D79DE4D8-249F-432C-8810-316846B6173BQ36845231-8DDFA788-048A-482A-83C9-EDA0F82C8AEFQ36869625-20DCA720-2306-4EF7-B5BE-AE987FA0549AQ37118150-D477549D-CBF7-432E-A1CA-168D4501F4BBQ37262415-8E493503-40C4-49FB-9350-4A0A2061D3A8Q37285232-917AF255-D019-4FEC-A779-DD7F05D4F6D7Q37312825-1D670E14-513D-49A4-8423-6D93EB9D842FQ37599845-F588DE6D-55C1-493C-A3E0-9380440C01DBQ37728011-F7F1BFC8-C123-4961-AD99-3120CA25D038Q37765590-605AFDE3-837E-4CFE-B728-0406CA204921Q37930988-41B9BA41-E4D8-45AA-A1AF-19434BD12DF6Q38090560-0D120E6F-CEEB-4052-AEF7-35E79EA71F67Q38666579-AB4C9369-AE1E-45F1-9188-232E5979F3B7Q39035696-26386D60-27CB-4E7E-B0E1-542DBDD64C7CQ39894616-0B1873D6-C912-42A4-89F6-B65C49E470ADQ45966276-8D04B470-C034-4B8D-B965-3ED6012B1EF3Q55094012-E39D476B-C6E6-4853-AF2A-39638447FB10
P2860
Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Unmasking immunosurveillance a ...... KT regulatory cells and IL-13.
@en
Unmasking immunosurveillance a ...... KT regulatory cells and IL-13.
@nl
type
label
Unmasking immunosurveillance a ...... KT regulatory cells and IL-13.
@en
Unmasking immunosurveillance a ...... KT regulatory cells and IL-13.
@nl
prefLabel
Unmasking immunosurveillance a ...... KT regulatory cells and IL-13.
@en
Unmasking immunosurveillance a ...... KT regulatory cells and IL-13.
@nl
P2093
P2860
P356
P1476
Unmasking immunosurveillance a ...... KT regulatory cells and IL-13.
@en
P2093
Debra D Donaldson
Jay A Berzofsky
Jong Myun Park
Leon T van den Broeke
Masaki Terabe
P2860
P356
10.1002/IJC.20669
P577
2005-03-01T00:00:00Z